PER® New York GU | Conference

Dr Bochner on Key Points for Community Oncologists in the Management of Muscle-Invasive Bladder Cancer

March 10th 2024

Bernard H. Bochner, MD, FACS, discusses considerations for community oncologists when treating patients with muscle-invasive bladder cancer.

Dr Xu on Treatment Sequencing Considerations in Metastatic Renal Cell Carcinoma

March 10th 2024

Wenxin (Vincent) Xu, MD, discusses the factors he takes into account when sequencing treatment options for patients with metastatic renal cell carcinoma.

Artificial Intelligence in Prostate Cancer Pathology: Friend or Foe?

March 9th 2024

Peter A. Humphrey, MD, PhD, presents on the standing of artificial intelligence in prostate cancer pathology.

Piecing the Puzzle Together: Treatment After Progression in Metastatic Castration-Resistant Prostate Cancer

March 9th 2024

The inter-tumoral complexity of metastatic castration-resistant prostate cancer poses a treatment challenge that may be tackled by examining clonal evolution.

Dr Tagawa on the Role of PARP Inhibitors in Prostate Cancer Treatment

March 9th 2024

Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the standing of PARP inhibitors in the treatment paradigm of metastatic castration-resistant prostate cancer.

Dr Dreicer on Improving Clinical Trial Design in Prostate Cancer

March 9th 2024

Robert Dreicer, MD, discusses the shortcomings of current clinical trials in prostate cancer and what he sees as the biggest area of improvement.

Precision Medicine: Brief But Impactful in Prostate Cancer Management

March 8th 2024

The burst of translational research leading to PARP inhibitors in prostate cancer, along with imaging and diagnostic advances, has been a monumental evolution for the management of this disease.

Further Understanding of Immune Mechanisms in Tumor Microenvironment Is Key to Advancing Immunotherapy in Solid Tumors

March 14th 2023

Although the immune system plays a vital role in attacking tumor cells, the immune mechanisms vary from tumor to tumor, and factors in the tumor microenvironment can reduce the effectiveness of the body’s immune response.

Navigating Systemic Therapy for RCC: Balancing Risk Status and Response

March 13th 2023

Despite a perhaps overwhelming number of combination regimens available for use in the frontline setting for patients with renal cell carcinoma, treatment decisions can still largely boil down to a patient’s risk status. For second-line therapy, investigators are looking to contemporary trials for guidance.

ADCs, Novel Targets Represent Next Wave of Treatment Advances in mCRPC

March 11th 2023

Patients with metastatic castration-resistant prostate cancer have traditionally been burdened by a poor outlook; however, emerging therapeutic targets and novel agents directed at them are poised to affect change in this population.

Precision Medicine in Prostate Cancer Care: Keeping Up With Evolving Guidance for Testing and Decision Making

March 10th 2023

Precision medicine has arrived in all stages of prostate cancer care and recommendations for optimal testing and how best to leverage the results to inform clinical decisions continue to rapidly evolve.

Radiotherapy Treatments Are Getting Shorter and Faster in Prostate Cancer

March 17th 2022

The history of radiation therapy for men with prostate cancer extends back more than a century. From those early crude methods, the field has advanced to delivery potentially curative therapies that can be administered in as little as 2 weeks.

Dr. Tagawa on Utilizing Bone-Targeting Radium-223 in Prostate Cancer

March 16th 2022

Scott T. Tagawa, MD, MS, FACP, discusses the use of radium-223 in prostate cancer.

Dr. Dreicer on the Impact of the CHAARTED Trial in mCSPC

March 16th 2022

Robert Dreicer, MD, discusses the impact of the phase 3 CHAARTED trial in metastatic castration-sensitive prostate cancer.

Precision Medicine Takes Hold of Prostate Cancer Management

March 16th 2022

The applications for germline and somatic genetic testing in prostate cancer have skyrocketed, carving out an important role in screening, diagnosis, and treatment.

Navigating Frontline RCC Treatment Paths Relies on Risk Stratification

March 16th 2022

Primo Nery Lara Jr, MD, provides an overview of the treatment landscape for patients with metastatic renal cell carcinoma.

Investigators Look Beyond Immune Checkpoint Inhibitors to Chase Moving Targets in Prostate Cancer

March 16th 2022

Immune checkpoint inhibitors represent only one area of effective therapy for patients with advanced prostate cancer, but they are not “be all, end all” of immunotherapy options.

ADT-Based Combinations Have Become Standard Therapy for Metastatic Castration-Sensitive Prostate Cancer

March 15th 2022

Overwhelming evidence has pointed to the use of androgen deprivation therapy in combination with 1 or 2 other agents as the standard of care for patients with metastatic castration-sensitive prostate cancer.

Neoadjuvant Chemotherapy Benefit Retains Stronghold for Patients With MIBC, UTUC

March 15th 2022

Effective treatment paths leveraging neoadjuvant chemotherapy have been well-established for patients with muscle-invasive bladder cancer, with mounting retrospective and prospective data continuing to demonstrate overall survival benefit compared with adjuvant chemotherapy.

Immunotherapy and Targeted Treatment Approaches Improve Outcomes in Metastatic Urothelial Cancer

March 14th 2022

Patients with metastatic urothelial carcinoma have multiple effective treatment options approved in both the first line and relapsed settings, with other promising agents and combinations currently in development.